Gastrointestinal perforation due to bevacizumab in colorectal cancer.
about
Preoperative, intraoperative and postoperative risk factors for anastomotic leakage after laparoscopic low anterior resection with double stapling technique anastomosisValue of bevacizumab in treatment of colorectal cancer: A meta-analysisAngiogenic inhibitors for older patients with advanced colorectal cancer: does the age hold the stage?Gastrointestinal Toxicities With Combined Antiangiogenic and Stereotactic Body Radiation TherapyIdentification of novel targets for antiangiogenic therapy by comparing the gene expressions of tumor and normal endothelial cellsRisk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study.Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review.Uncommon acquired fistulae involving the digestive system: summary of data.Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancerSafety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials.Endoscopy in patients with diarrhea during treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitors: Is the cause in the mucosa?Perioperative chemotherapy with bevacizumab and liver resection for colorectal cancer liver metastasisSafety of endoscopy in cancer patients on antiangiogenic agents: A retrospective multicenter outcomes study.Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitorsRetroperitoneal metastatic adenocarcinoma complicated with necrotizing fasciitis of the thigh in a patient with advanced rectal colon cancer.Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review.Bowel perforation after erlotinib treatment in a patient with non-small cell lung cancer.Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study.The current state of targeted agents in rectal cancer.A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515.Periodontal disease in a patient receiving Bevacizumab: a case reportGastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation.The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived?Multiple large bowel resections: potential risk factor for anastomotic leak.Targeted therapies in colorectal cancer: surgical considerations.Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma.Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II ConsortiaShould noncurative resection of the primary tumour be performed in patients with stage iv colorectal cancer? A systematic review and meta-analysis.Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer.Managing patients with metastatic colorectal cancer on bevacizumab.Evidence for the role of bevacizumab in the treatment of advanced metastatic breast cancer: a review.Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges.Toxicity associated with the long-term use of targeted therapies in patients with advanced renal cell carcinoma.Palliative treatment of unresectable metastatic colorectal cancer.Targeted therapies in the management of colorectal carcinoma: role of bevacizumab.Evolution of the management of colorectal cancer using integrative medicine.Monoclonal antibodies and antibody fragments: state of the art and future perspectives in the treatment of non-haematological tumors.Chemotherapy with bevacizumab for metastatic colorectal cancer: a retrospective review of 181 Japanese patients.What the emergency radiologist needs to know about treatment-related complications from conventional chemotherapy and newer molecular targeted agents.Tumor-bowel fistula: what radiologists should know.
P2860
Q26739044-523D5149-E5BA-46C5-8A76-3AF23896AD34Q26849789-E890E091-0A14-41B8-B082-25DA37878785Q27002538-75BF3094-816F-4746-A1F6-A3086FCCBF61Q28086904-F4D3A223-FF34-4230-99C7-BCEB7201A4DFQ28650438-9C7F1928-1021-4DAC-B6CD-43365943B15EQ30405727-755F2B1D-7417-495A-91E1-893B3FB862BCQ30922171-500D5B1B-F7F0-4846-AB4F-B29968F5844FQ31040283-BDAD752C-D1CB-43F0-AE8D-F6FC2A8E04FFQ33384357-42DCC45C-4546-4E4F-943F-6DF06375B8EEQ33392652-0E92DB2D-B7BB-41B8-826F-E776546295AFQ33467424-60E88AB1-BC50-4C40-9C77-890F0F777073Q33622791-9750DB20-FFEF-4827-A0CF-91788D7AEB70Q33637887-78FEA5C1-E2BF-43B3-B485-E35190F4FF8FQ33698419-31C2DEAF-5D65-41CC-8E58-D77C44378117Q34587596-F4622FC7-17EA-4849-BDF3-E3C034DDFC3DQ35009777-84D5015F-9E18-4BAF-B700-9C48534D90D8Q35014817-D3464A29-9A28-48F8-B808-B496DD6384F6Q35035576-389DF844-D175-4BE5-B698-BEB92833775DQ35996651-AC4DF271-4F45-401B-AA3A-BD660BCC575CQ36163040-C1A17BD6-7F6F-42E9-937E-84EA7761AA3FQ36488800-B4E9D8CD-36E8-47FA-B202-A9A0DAB9C33FQ36784813-37A4B8FD-CE80-4BF5-B68F-FE35ADC5BCC9Q36792745-83C19283-F330-46A6-9B7D-00F7ED3387D6Q36941095-C661CB55-928B-4C70-A484-0647773819C3Q37015697-3A8BE207-B8AD-46B5-8A5B-E44972AAFA90Q37081896-80B5A8EC-E885-49FA-A96B-21ABD5795F35Q37235598-07440A8C-08FB-4484-A8D0-7B9CF24D26ECQ37248008-F937C544-5A2F-4930-8733-5DAA98E3A845Q37316035-01FFC4B7-3F45-4E3A-B804-0BBF57671725Q37316862-09C5D8B6-9A5E-470A-8041-EE13962DDB92Q37355708-3F1FBA63-4C8C-441F-92BB-A753DE9F3821Q37485865-4C1A4EBE-3423-4502-AFAA-9C9E5EBF3C28Q37508022-8F9CFD08-6809-457E-BF2D-32219EC7F9AFQ37650308-DA44E27E-96BA-4B13-B6DF-F2D58BC36918Q37771243-10DD1FB2-DC11-48EB-9FD9-05D71D9FF737Q37831826-DC878C15-02B9-446E-A546-45982BE97AFCQ37887819-D4EBC73C-BAD5-4526-8B29-10CAF79CA4EBQ38016098-07262F1A-D205-4986-BA07-811524EADD80Q38016741-A02EC418-E114-4315-9472-2A08DE4E98AEQ38086054-D9E48047-0AF6-40AB-8056-D1C91AF382A6
P2860
Gastrointestinal perforation due to bevacizumab in colorectal cancer.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Gastrointestinal perforation due to bevacizumab in colorectal cancer.
@ast
Gastrointestinal perforation due to bevacizumab in colorectal cancer.
@en
type
label
Gastrointestinal perforation due to bevacizumab in colorectal cancer.
@ast
Gastrointestinal perforation due to bevacizumab in colorectal cancer.
@en
prefLabel
Gastrointestinal perforation due to bevacizumab in colorectal cancer.
@ast
Gastrointestinal perforation due to bevacizumab in colorectal cancer.
@en
P2093
P1476
Gastrointestinal perforation due to bevacizumab in colorectal cancer.
@en
P2093
Aymen Elfiky
Muhammad Wasif Saif
Ronald R Salem
P2888
P304
P356
10.1245/S10434-006-9337-9
P577
2007-03-14T00:00:00Z
P6179
1050932420